A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.

The government hopes to limit cases in which NICE determines a treatment isn't cost effective after the MHRA has deemed it ...

In the third phase, the Diagnostics Accelerator will support the development of multi-marker panels leveraging digital and AI tools that can accelerate precision treatments.

BriGene Biosciences supported Grit with technology transfer, manufacturing, and regulatory requirements for the IND for GT307.

Early clinical data indicates the treatment leads to dose-dependent increases in functional AAT protein, which is altered in the condition.